ADMA Biologics (ADMA) Stock Analysis & AI Equity Report
ADMA Biologics (ADMA) overview
ADMA Biologics (ADMA) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 510m and operating profit of USD 191m; the year-end share price was 18.24 USD and market capitalisation was USD 4,339m. ADMA Biologics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get ADMA Biologics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About ADMA Biologics
ADMA Biologics develops, manufactures and markets specialty biologic therapies for people with immune deficiencies and others at risk of certain infectious diseases. Its marketed products include intravenous immune globulin therapies for primary immunodeficiency and hepatitis B immune globulin for specified exposures. The company also operates U.S. plasma collection centers and develops plasma-derived therapeutic candidates for clinical use.
Generate the ADMA Biologics report
ADMA Biologics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for ADMA Biologics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on ADMA Biologics
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.